CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) reported Net Margin of 8431.48% for Q1 2026, up 728956.0% on a YoY basis from N/an in Q1 2025, and up 55.1% sequentially from 18778.36% in Q4 2025.
CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 11 years of Net Margin data on file, last reported at 8431.48% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 728956.0% year-over-year to 8431.48%; the trailing twelve-month figure through Mar 2026 stood at 14627.49% (down 1467590.0% YoY), and the FY2025 full-year result was 17470.4%, down 1757129.0% from the prior year.
- Net Margin grew to 8431.48% in Q1 2026, from 18778.36% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1027.11% in Q4 2024 to a low of 1842916.67% in Q4 2022.
- A 5-year average of 144032.27% and a median of 17249.7% in 2025 frame the typical range for Net Margin.
- Across the five-year window, Net Margin plunged 184182164 bps in 2022 and surged 184296109 bps in 2023, its largest moves.
- Tracing CRSP's Net Margin over 5 years: stood at 1842916.67% in 2022, then soared by 100 bps to 44.43% in 2023, then jumped by 2212 bps to 1027.11% in 2024, then tumbled by 1928 bps to 18778.36% in 2025, then surged by 55 bps to 8431.48% in 2026.
- Business Quant data shows CRSP's Net Margin at 8431.48% in Q1 2026, 18778.36% in Q4 2025, and 11973.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -8,431.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,431.48% |
| Dec 31, 2025 | -18,778.36% |
| Sep 30, 2025 | -11,973.12% |
| Jun 30, 2025 | -23,379.93% |
| Mar 31, 2025 | -15,721.04% |
| Dec 31, 2024 | 1,027.11% |
| Sep 30, 2024 | -14,276.08% |
| Jun 30, 2024 | -24,452.80% |
| Mar 31, 2024 | -23,133.13% |
| Dec 31, 2023 | 44.43% |
| Jun 30, 2023 | -111.06% |
| Mar 31, 2023 | -53.07% |
| Dec 31, 2022 | -1,842,916.67% |
| Sep 30, 2022 | -185,690.43% |
| Jun 30, 2022 | -117,605.06% |
| Mar 31, 2022 | -19,065.64% |
| Dec 31, 2021 | -1,095.03% |
| Sep 30, 2021 | -15,430.58% |
| Jun 30, 2021 | 84.29% |
| Mar 31, 2021 | -20,994.99% |